Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications. They are made of a payload, a linker, and an antibody. Usually, they are classified as Highly Potent APIs (HPAPIs) compounds due to the payload. Handling and manufacturing can be challenging due to the strict requirements for containment. As more of these complex products enter clinical development, the need to scale up production of their payloads becomes a pressing topic. In this webinar, participants will hear about Lonza’s investment in facilities capable of producing large quantities (100+ kg) under the strictest levels of containment.

• Market drivers
• Design concepts
• Facility overview

• Key market trends
• Lonza’s approach to lifecycle investment
• Leadership in highly-potent API facility and process design